1. Introduction
===============

Human osteosarcoma is one of the most common malignant bone tumors in children and young adult, with high mortality and disability.^\[[@R1],[@R2]\]^ The cancer is characterized by high propensity to metastasize and locally relapse.^\[[@R3]\]^ Along with the development of comprehensive therapies, the 5-year survival rate among osteosarcoma patients is up to 60% to 70%, but over 50% osteosarcoma cases present metastasis when initially diagnosed, especially lung metastases, and the 5-year survival rate in these cases is \<30%.^\[[@R4],[@R5]\]^ Until now, measures for osteosarcoma early diagnosis and prognosis are still unsatisfactory. Therefore, it is necessary to identify key components in osteosarcoma origination and development, thus contributing to the malignancy diagnosis, treatment, and prognosis.

Wingless-Type MMTV Integration Site Family, Member 6 (WNT6), located in chromosome 2q35, belongs to the WNT gene family showing diverse functions on cell fate, proliferation, migration, polarity, and death.^\[[@R6]\]^ In previous studies, WNT6 was initially considered as a canonical WNT signaling molecule expressed strongly in epithelium.^\[[@R7]\]^ With the advancement in molecular techniques, WNT6 dysregulation has already been observed in various pathological conditions, such as renal fibrosis, cleft palate, and recurrent miscarriage.^\[[@R8]--[@R10]\]^ Recently, the effects of WNT6 on cancers have attracted increasing attentions. Growing evidences have suggested that WNT6 over-expression is associated with various human cancers, including colorectal cancer^\[[@R11]\]^ and gastric cancer.^\[[@R6]\]^ However, the role of WNT6 in osteosarcoma is still unclear.

In this study, we aimed to investigate the expression of WNT6 in osteosarcoma tissues and its relationship with clinicopathologic characteristics. Besides, clinical significance of WNT6 for early detection and prognosis evaluation in osteosarcoma were also estimated.

2. Materials and methods
========================

2.1. Patients and samples
-------------------------

This study was conducted in Fudan University and approved by the Ethic Committee of the hospital. Around 88 osteosarcoma patients were collected who were diagnosed during 2011 to 2013 and had a median age of 20.89 ± 6.64. Besides, 32 patients with Ewing\'s sarcoma and 20 patients with osteomyelitis were recruited in the study as well. None of the patients had received any preoperative treatments, either chemotherapy or radiotherapy. In addition, the same number of healthy people who were matched with the cases in age (±5 years), sex and residential area were enrolled as controls. All participants signed informed consents in advance.

Osteosarcoma tissues and adjacent normal ones were collected from osteosarcoma patients. Besides, similar operations were also conducted for the healthy people, Ewing\'s sarcoma patients, and osteomyelitisthe cases. Then the tissues were immediately frozen in liquid nitrogen, and stored at −80°C for RNA extraction. Fasting blood samples were collected for all participants using blood collection tube with Ethylenediaminetetraacetic acid. Serum specimens were isolated from the blood samples through centrifugation, and then stored at −80°C for subsequent analysis. The levels of WNT6 mRNA and protein were detected via quantitative real-time polymerase chain reaction (qRT-PCR) and enzyme lined immunosorbent assay (ELISA), respectively.

2.2. QRT-PCR assay
------------------

Total RNA was extracted from the tissue and serum samples applying Trizol reagent (Invitrogen) according to the manufacturer\'s instructions. Reverse transcription was carried out to synthesize the first chain of cDNA using the Omniscript RT kit (Qiagen, Valencia, CA). RT-PCR reaction was conducted in Applied Biosystems 7500 real-time PCR system (Applied Biosystems, Foster City, CA). RNU6 was used as endogenous control for WNT6 expression. WNT6 expression relative to RNU6 in tissue and serum was calculated using the 2^-△△CT^ method. All samples were examined in triplicate.

2.3. ELISA assay
----------------

Total protein was isolated on the basis the obtained tissue samples using the protein extraction kit (Bestbio, China) according to the manufacturer\'s instructions. The isolated protein samples were quantified via BCA assay (Thermo Scientific). ELISA analysis was performed using Human Protein Wnt-6 (WNT6) ELISA kit (CSB-EL026140HU, CUSABIO, China), and detailed protocols were as follows: the protein was loaded to each well of a 96-well immunoplate (Nunc, Denmark), and incubated overnight at 4°C; the plates were then washed with PBS and blocked with 5% BSA/PBS for 2 hours at room temperature; after washing with PBS again, biotin-conjugated antibody was added to the wells and incubated for 1 hour at room temperature; later, 50 μL HRP chromogenic substrate was put into each well of the plates to develop signals for 30 minutes at room temperature. The absorbance was read using an ELISA reader (Benchmark Microplate Reader; Bio-Rad, Hercules, CA).

2.4. Follow-up
--------------

A 5-years follow-up was performed among the osteosarcoma patients. The overall survival time was defined as the duration between the diagnosis day and the death day or the date at the end of the follow-up. Telephone inquiring or questionnaire was adopted to collect participants' information during the follow-up. Clinicopathologic characteristics such as age, sex, tumor grade, tumor diameter, distant metastasis, tumor location, and recurrence were recorded in a database.

2.5. Statistical analysis
-------------------------

Statistical analyses were performed using SPSS 18.0 software. Differences in *WNT6* expression between osteosarcoma patients and the controls were analyzed adopting Students' *t* test. The relationship between *WNT6* and clinicopathologic characteristics was evaluated through chi-square test. Receiver operating characteristic (ROC) curve was constructed to evaluate *WNT6* diagnostic value. The association between *WNT6* and overall survival was estimated utilizing Kaplan--Meier and cox regression analysis. Results would be statistically significant if *P* value was less than 0.05.

3. Results
==========

3.1. Increased expression of WNT6 mRNA in osteosarcoma tissues and serum
------------------------------------------------------------------------

The expression of *WNT6* at mRNA level was detected through qRT-PCR. The result demonstrated that *WNT6* expression was markedly upregulated in osteosarcoma tissues compared with the adjacent and healthy ones (Fig. [1](#F1){ref-type="fig"}, *P \< *.05). Besides, the expression of serum *WNT6* mRNA was also tested for osteosarcoma patients, Ewing\'s sarcoma patients, osteomyelitis patients, and healthy controls. The outcomes showed that serum *WNT6* expression was higher in osteosarcoma patients than in other patients and healthy controls (Fig. [2](#F2){ref-type="fig"}, *P \< *.05).

![The expression of *WNT6* mRNA in osteosarcoma, adjacent nontumor and healthy tissues. *WNT6* expression was higher in osteosarcoma tissues than in adjacent and healthy ones (*P \< *.05). *WNT6* = Wingless-Type MMTV Integration Site Family, Member 6.](medi-97-e13011-g001){#F1}

![The expression of serum *WNT6* mRNA in osteosarcoma patients, ewing\'s sarcoma individuals, osteomyelitis cases and healthy controls. Serum *WNT6* expression was higher in osteosarcoma patients than in other cases and healthy controls (*P \< *.05). *WNT6* = Wingless-Type MMTV Integration Site Family, Member 6.](medi-97-e13011-g002){#F2}

3.2. The expression of WNT6 at protein level
--------------------------------------------

*WNT6* protein expression was measured using ELISA. The results indicated that the expression of *WNT6* protein was higher in osteosarcoma patients than in healthy controls (Fig. [3](#F3){ref-type="fig"}, *P \< *.05), which was in accordance with the outcome from qRT-PCR.

![The expression of *WNT6* protein in osteosarcoma, adjacent cancer-free and healthy tissues. *WNT6* protein expression was higher in osteosarcoma tissues than in adjacent and healthy ones (*P \< *.05). *WNT6* = Wingless-Type MMTV Integration Site Family, Member 6.](medi-97-e13011-g003){#F3}

3.3. Association between WNT6 and clinicopathologic characteristics
-------------------------------------------------------------------

In this study, we also analyzed the association between *WNT6* and clinicopathologic characteristics among osteosarcoma patients. No significant correlation was found for *WNT6* with sex, tumor diameter, tumor location, or recurrence (*P \> *.05 for all). However, WNT6 expression showed close association with patients' age (*P \< *.001), tumor grade (*P \< *.001), and distant metastasis (*P = *.001) (Table [1](#T1){ref-type="table"}).

###### 

Association between *WNT6* and clinicopathologic characteristics in osteosarcoma patients.

![](medi-97-e13011-g004)

3.4. The diagnostic value of WNT6 in osteosarcoma
-------------------------------------------------

In the study, we used ROC curve to analyze the diagnostic value of serum *WNT6* in osteosarcoma (Fig. [4](#F4){ref-type="fig"}). The AUC value was 0.854, with a specificity of 88.4% and a sensitivity of 77.8%, suggesting a splendid performance for WNT6 in osteosarcoma diagnosis. The cut off value was 4.255.

![The ROC curve of *WNT6.* The AUC was 0.854 with a cut off value of 4.255, while the specificity and sensitivity were 88.4% and 77.8%, respectively. ROC = receiver operating characteristic, *WNT6* = Wingless-Type MMTV Integration Site Family, Member 6.](medi-97-e13011-g005){#F4}

3.5. The relationship between WNT6 and overall survival in patients with osteosarcoma
-------------------------------------------------------------------------------------

Kaplan--Meier analysis indicated that osteosarcoma patients with high *WNT6* expression had shorter survival time than those with low expression (Fig. [5](#F5){ref-type="fig"}, log rank test *P = *.001). Cox regression analysis manifested that distant metastasis (HR = 0.327, 95%CI = 0.129--0.823, *P = *.018), recurrence (HR = 0.354, 95%CI = 0.146--0.856, *P = *.021) and *WNT6* expression (HR = 2.227, 95%CI = 1.061--10.842, *P = *.027) were important factors affecting osteosarcoma prognosis (Table [2](#T2){ref-type="table"}).

![The Kaplan--Meier analysis on *WNT6* in osteosarcoma patients. As shown in the curve, osteosarcoma patients with high *WNT6* expression had shorter survival time than those with low levels (*P \< *.001). *WNT6* = Wingless-Type MMTV Integration Site Family, Member 6.](medi-97-e13011-g006){#F5}

###### 

COX regression for the relationship between clinicopathological features and *WNT6* expression.
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4. Discussion
=============

Osteosarcoma is caused by genetic changes that interrupt osteoblast differentiation from mesenchymal stem cells.^\[[@R12],[@R13]\]^ Due to the unclear molecular mechanism, it is difficult to identify key factors for osteosarcoma development.^\[[@R14]\]^ In order to improve clinical outcomes of osteosarcoma patients, it is of great importance to explore molecular mechanism of this malignancy.

Wnt signal pathway has been confirmed to be related to the occurrence of osteosarcoma.^\[[@R15]\]^ Disorder in the functions of Wnt signal transduction causes abnormalities in cell proliferation and in downstream genes' expressions, thus leading to various malignant tumors, such as colorectal cancer, neuroblastomas, and thyroid cancer.^\[[@R16]--[@R18]\]^*WNT6* gene is an important member of *WNT* gene family, and plays critical roles in various biological processes including embryogenesis, epithelial formation, and cell--cell communication.^\[[@R8],[@R19],[@R20]\]^ The association of *WNT6* with cancers has already been reported in some previously published studies. In the study by Galbraith et al,^\[[@R21]\]^*WNT6* gene was upregulated in colorectal adenoma and associated with the cancer malignant degree. Yuan et al^\[[@R6]\]^ found *WNT6* upregulation could enhance epirubicin resistance in gastric cancer. *WNT6* is expressed specifically by macrophage clusters within granulomatous lesions and possesses a distinctively immunomodulatory potential.^\[[@R22]\]^*WNT6* has also been linked to the metastasis of melanoma and breast carcinoma.^\[[@R23]\]^ Previous study has shown that *WNT6* can induce satellite-cell quiescence as well as nuclear translocation of Act-beta-Cat appearing in acute and chronic skeletal muscle regeneration in rodents and humans.^\[[@R24]\]^ While the study by Li et al^\[[@R25]\]^ demonstrated that DNA methylation of *WNT6* was low in children with osteosarcoma, which might contribute to malignant progression. However, whether the *WNT6* gene is associated with osteosarcoma progression in adults is rarely reported.

In our study, the expression of *WNT6* mRNA and protein was detected in osteosarcoma patients. The results showed that the mRNA and protein levels of *WNT6* were markedly upregulated in osteosarcoma tissues when compared to the adjacent and healthy ones. Similarly, serum *WNT6* expression in osteosarcoma patients was much higher than that in other patients and healthy controls. Then we further analyzed the relationship between *WNT6* and clinicopathologic characteristics. *WNT6* expression was uncovered to be significantly associated with age and distant metastasis. The results revealed that *WTN6* might contribute to osteosarcoma development.

In addition, we evaluated the diagnostic and prognostic value of *WNT6* in osteosarcoma. ROC curve was constituted to evaluate the diagnostic value for *WNT6*, and obtained an AUC value of 0.854, with a specificity of 88.4%, a sensitivity of 77.8% and a cut-off value of 4.255. All of these data suggested that *WNT6* gene could be a diagnostic biomarker in osteosarcoma. Kaplan--Meier analysis showed that patients with relatively higher *WNT6* expression survived significantly shorter than those with low levels. Meanwhile, cox regression analysis verified that *WNT6* expression was a crucial indicator for osteosarcoma prognosis.

Several limitations in the current study should be stated here. Firstly, the sample size was relatively small, which might reduce the statistical power of our study. Secondly, molecular mechanisms underlying the functional roles of WNT6 in osteosarcoma development and progression remained unclear. Cell and animal experiments should be performed to address this issue. Additionally, all of the study subjects were collected from one region, and the conclusions obtained from our study might be less applicable for other populations. Therefore, further researches with larger sample sizes are required to verify and improve our conclusions.

In conclusion, *WNT6* is upregulated in osteosarcoma and its expression is closely correlated with age and distant metastasis. *WNT6* may be an independent diagnostic and prognostic biomarker for osteosarcoma.
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